



# ADC先导分子开发与筛选

抗体偶联药物( antibody-drug conjugate, ADC) 是将单克隆抗体药物的高特异性和小分子细胞毒药物的高活性相结合, 用以提高肿瘤药物的靶向性、减少毒副作用。ADC抗体分子的筛选是ADC临床转化前的重要基础, 是保证ADC临床有效性和安全性的关键。缔码生物针对每个ADC热门靶点, 已经开发出几十种预先开发好的先导分子, 同时建立了一整套ADC临床前药效学评价平台。



ADC作用机制



已开发的ADC先导分子热门靶点

## 平台优势



**现货**

- 热门ADC靶点的现货分子转让, 即刻引进测试
- ADC靶点先导分子库**80+**, B细胞种子库**100+**



**丰富的经验**


- 已转让ADC项目**10+**
- 正在测试的项目**20+**



**赋能ADC开发**


- 高灵敏, 低背景的内吞试剂
- 抗Payload/Linker单抗 (MMAE, Dxd, Eribulin, SN38, DM1, CL2A (ADC linker))

## 平台流程




## DiTag™ IgG labeling reagent

### pH sensitive IgG labeling reagent




### MMAE IgG labeling reagent



## Anti-payload/Linker rabbit antibody


### MMAE

ELISA assay to evaluate Anti-MMAE antibody  
0.2µg Human IgG-MMAE per well




### SN38

ELISA assay to evaluate Anti-SN38 Antibody  
0.2µg BSA-SN38 per well




### Dxd

ELISA assay to evaluate Anti-Dxd Antibody  
0.2µg Human IgG-Dxd per well




### Eribulin

ELISA assay to evaluate Eribulin-Antibody  
0.2µg Human IgG-Eribulin per well




### DM1

ELISA assay to evaluate Anti-DM1 Antibody  
0.2µg BSA-DM1 per well




### CL2A (ADC linker)

ELISA assay to evaluate Anti-CL2A Antibody  
0.2µg Human IgG-CL2A per well



## 案例展示

### Cytotoxicity assay of GPRC5D antibody-drug conjugate (ADC) conjugated with MMAE



Ab1、Ab2: DIMA Lead antibodies against human GPRC5D; Cell line: K562 (negative control), K562-GPRC5D (positive cells), and H929 (GPRC5D-expressing natural cell line)

In this experiment, the data demonstrates the specific cytotoxicity of anti-GPRC5D antibodies against GPRC5D-positive cells following MMAE conjugation.

